| Adverse events . | With nituzumab (n = 39) . | Without nituzumab (n = 17) . | χ2 . | P . |
|---|---|---|---|---|
| Grades 1-2 (n, %) . | Grades 1-2 (n, %) . | |||
| Leukopenia | 20(51.3) | 8(47.1) | 0.084 | .771 |
| Neutropenia | 13(33.3) | 5(29.4) | 0.083 | .773 |
| Thrombocytopenia | 9(23.1) | 4(23.5) | 0.000 | 1.000 |
| Fever | 1(2.6) | 0(0) | 1.000 | |
| Dizziness | 1(2.6) | 0(0) | 1.000 | |
| Vomiting | 4(10.3) | 5(29.4) | 1.957 | .162 |
| Rash | 4(10.3) | 0(0) | 0.650 | .420 |
| Fatigue | 2(5.1) | 0(0) | 0.044 | .834 |
| Constipation | 2(5.1) | 0(0) | 0.044 | .834 |
| ALT/AST elevation | 1(2.6) | 1(5.9) | 0.000 | 1.000 |
| Adverse events . | With nituzumab (n = 39) . | Without nituzumab (n = 17) . | χ2 . | P . |
|---|---|---|---|---|
| Grades 1-2 (n, %) . | Grades 1-2 (n, %) . | |||
| Leukopenia | 20(51.3) | 8(47.1) | 0.084 | .771 |
| Neutropenia | 13(33.3) | 5(29.4) | 0.083 | .773 |
| Thrombocytopenia | 9(23.1) | 4(23.5) | 0.000 | 1.000 |
| Fever | 1(2.6) | 0(0) | 1.000 | |
| Dizziness | 1(2.6) | 0(0) | 1.000 | |
| Vomiting | 4(10.3) | 5(29.4) | 1.957 | .162 |
| Rash | 4(10.3) | 0(0) | 0.650 | .420 |
| Fatigue | 2(5.1) | 0(0) | 0.044 | .834 |
| Constipation | 2(5.1) | 0(0) | 0.044 | .834 |
| ALT/AST elevation | 1(2.6) | 1(5.9) | 0.000 | 1.000 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
| Adverse events . | With nituzumab (n = 39) . | Without nituzumab (n = 17) . | χ2 . | P . |
|---|---|---|---|---|
| Grades 1-2 (n, %) . | Grades 1-2 (n, %) . | |||
| Leukopenia | 20(51.3) | 8(47.1) | 0.084 | .771 |
| Neutropenia | 13(33.3) | 5(29.4) | 0.083 | .773 |
| Thrombocytopenia | 9(23.1) | 4(23.5) | 0.000 | 1.000 |
| Fever | 1(2.6) | 0(0) | 1.000 | |
| Dizziness | 1(2.6) | 0(0) | 1.000 | |
| Vomiting | 4(10.3) | 5(29.4) | 1.957 | .162 |
| Rash | 4(10.3) | 0(0) | 0.650 | .420 |
| Fatigue | 2(5.1) | 0(0) | 0.044 | .834 |
| Constipation | 2(5.1) | 0(0) | 0.044 | .834 |
| ALT/AST elevation | 1(2.6) | 1(5.9) | 0.000 | 1.000 |
| Adverse events . | With nituzumab (n = 39) . | Without nituzumab (n = 17) . | χ2 . | P . |
|---|---|---|---|---|
| Grades 1-2 (n, %) . | Grades 1-2 (n, %) . | |||
| Leukopenia | 20(51.3) | 8(47.1) | 0.084 | .771 |
| Neutropenia | 13(33.3) | 5(29.4) | 0.083 | .773 |
| Thrombocytopenia | 9(23.1) | 4(23.5) | 0.000 | 1.000 |
| Fever | 1(2.6) | 0(0) | 1.000 | |
| Dizziness | 1(2.6) | 0(0) | 1.000 | |
| Vomiting | 4(10.3) | 5(29.4) | 1.957 | .162 |
| Rash | 4(10.3) | 0(0) | 0.650 | .420 |
| Fatigue | 2(5.1) | 0(0) | 0.044 | .834 |
| Constipation | 2(5.1) | 0(0) | 0.044 | .834 |
| ALT/AST elevation | 1(2.6) | 1(5.9) | 0.000 | 1.000 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
